Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000352653 | SCV000344176 | pathogenic | not provided | 2016-08-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001230047 | SCV001402515 | pathogenic | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2; Autosomal recessive limb-girdle muscular dystrophy type 2N | 2019-07-06 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in POMT2 are known to be pathogenic (PMID: 15894594). Experimental studies have shown that this variant disrupts mRNA splicing (PMID: 17559086). Disruption of this splice site has been observed in several individuals affected with muscular dystrophy-dystroglycanopathy (PMID: 17559086, 18752264, 26495167). ClinVar contains an entry for this variant (Variation ID: 289765). This variant is not present in population databases (ExAC no frequency). This sequence change affects an acceptor splice site in intron 7 of the POMT2 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. |